Study of SYS6041 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to be generally well enough to care for yourself (ECOG score 0 or 1).
- You must have a tumor that can be measured on scans.
- You need to provide a tumor tissue sample for FRα testing.
- If you have ovarian, endometrial, lung, or breast cancer that has progressed after standard therapy, you may qualify for the first part of the study.
- You must agree to use reliable contraception during and after the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a new drug called SYS6051 is safe and effective for people with advanced solid tumors (cancer that has spread). Researchers will evaluate how well your body tolerates the drug and monitor for side effects.
This clinical trial tests a new investigational drug (SYS6010) combined with another drug (SYH2051) or given alone, compared to standard chemotherapy, for advanced breast cancer and other solid tumors that have a specific protein called EGFR. The goal is to see if this treatment can help shrink tumors or slow their growth.
This trial tests whether adding a new drug called SYS6006 to an existing cancer treatment (enlonstobart) works better than enlonstobart alone for advanced solid tumors that cannot be surgically removed. The goal is to see if the combination helps shrink tumors and improve survival.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new drug called SYN608 for people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. It looks for a specific genetic change (BRCA mutation or related DNA repair problem) to see if the drug might work better for you.
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.